Corporate executives invest considerable resources in architecting organizational culture. They craft eloquent mission statements, define core corporate values, host elaborately... Read more
Category: Uncategorized
The psychological trap of workspace AI: When employees seek empathy from algorithms
The reality: Anthropomorphizing digital tools into emotional anchors An unprecedented paradigm shift is altering modern corporate life: for the first... Read more
Bayer to present new Phase III KERENDIA data across broader CKD populations at ERA 2026
Bayer has officially announced that new investigational datasets from its Phase III KERENDIA® (finerenone) clinical development program will be showcased... Read more
Alkem launches India’s first pre-filled Semaglutide syringes for diabetes and obesity management
Alkem Laboratories has officially announced the commercial launch of semaglutide delivered via single-shot pre-filled syringes. With this deployment, Alkem cements... Read more
Singapore becomes first Asia-Pacific market to approve MSD’s Enflonsia for RSV prevention in infants
Singapore’s Health Sciences Authority (HSA) has officially approved MSD’s Enflonsia (clesrovimab). The therapeutic asset is indicated for the prevention of... Read more
Microsoft and Mayo Clinic partner to develop a specialized Frontier AI model for clinical medicine
Technology giant Microsoft and renowned healthcare network Mayo Clinic have announced a strategic partnership to develop a pioneering frontier artificial... Read more
MiniMed and Abbott expand strategic alliance to pioneer dual Glucose-Ketone sensor technology
Diabetes technology leader MiniMed has announced an expanded strategic partnership with Abbott to develop and commercialize proprietary dual glucose-ketone sensors.... Read more
Eli Lilly secures license for Ascidian’s gene-editing tech in a rare kidney disease pact valued up to $1.9 billion
U.S. pharmaceutical major Eli Lilly and Co. has entered into a definitive global licensing agreement with biotechnology firm Ascidian Therapeutics... Read more
British drug-cost watchdog recommends AbbVie’s Elahere for hard-to-treat ovarian cancer
The National Institute for Health and Care Excellence (NICE), the United Kingdom's cost-effectiveness watchdog, has officially recommended AbbVie's targeted "guided... Read more









